Skip to main content

Advertisement

SpringerLink
Log in

Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi). HDACi play a key role in epigenetic regulation of gene expression and have been increasingly used as anticancer agents. Recent studies suggest that VPA is associated with improved survival in high-grade gliomas. However, effects on lower grade gliomas have not been examined. This study investigates whether use of VPA correlates with tumor grade, histological progression, progression-free and overall survival (OS) in grade II, III, and IV glioma patients. Data from 359 glioma patients (WHO II–IV) treated with temozolomide plus an antiepileptic drug (VPA or another antiepileptic drug) between January 1997 and June 2013 at the Massachusetts General Hospital was analyzed retrospectively. After confounder adjustment, VPA was associated with a 28 % decrease in hazard of death (p = 0.031) and a 28 % decrease in the hazard of progression or death (p = 0.015) in glioblastoma. Additionally, VPA dose correlated with reduced hazard of death by 7 % (p = 0.002) and reduced hazard of progression or death by 5 % (p < 0.001) with each 100 g increase in total dose. Conversely, in grade II and III gliomas VPA was associated with a 118 % increased risk of tumor progression or death (p = 0.014), and every additional 100 g of VPA raised the hazard of progression or death by 4 %, although not statistically significant (p = 0.064). Moreover, grade II and III glioma patients taking VPA had 2.17 times the risk of histological progression (p = 0.020), although this effect was no longer significant after confounder adjustment. In conclusion, VPA was associated with improved survival in glioblastoma in a dose-dependent manner. However, in grade II and III gliomas, VPA was linked to histological progression and decrease in progression-free survival. Prospective evaluation of VPA treatment for glioma patients is warranted to confirm these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 16(Suppl 4):63. doi:10.1093/neuonc/nou223

    Article  Google Scholar 

  2. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre J-YY (2012) Primary brain tumours in adults. Lancet 379:1984–1996. doi:10.1016/S0140-6736(11)61346-9

    Article  PubMed  Google Scholar 

  3. Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, Bessaoud F, Bauchet F, Attaoua R, Fabbro-Peray P, Fabbro M, Kerr C, Taillandier L, Duffau H, Figarella-Branger D, Costes V, Bauchet L, Société Française de Neuropathologie SFdN, Club de Neuro-Oncologie of the Société Française de N, Association des Neuro-Oncologues d’Expression Française (ANOCEF) (2011) French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol 21(6):633–644. doi:10.1111/j.1750-3639.2011.00491.x

    Article  PubMed  Google Scholar 

  4. Hardesty DA, Sanai N (2011) The value of glioma extent of resection in the modern neurosurgical era. Front Neurol 3:140. doi:10.3389/fneur.2012.00140

    Google Scholar 

  5. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. doi:10.3171/jns.2001.95.2.0190

    Article  CAS  PubMed  Google Scholar 

  6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff R-OO, for, of, Groups E, of Group N (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi:10.1016/S1470-2045(09)70025-7

    Article  CAS  PubMed  Google Scholar 

  7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine 352:987–996. doi:10.1056/NEJMoa043330

    Article  CAS  PubMed  Google Scholar 

  8. Price RL, Chiocca EA (2014) Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. Neurosurgery 61(Suppl 1):74–83. doi:10.1227/NEU.0000000000000390

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kumthekar P, Raizer J, Singh S (2015) Low-grade glioma. Cancer Treat Res 163:75–87. doi:10.1007/978-3-319-12048-5_5

    Article  PubMed  Google Scholar 

  10. Pouratian N, Schiff D (2010) Management of low-grade glioma. Curr Neurol Neurosci Rep 10:224–231. doi:10.1007/s11910-010-0105-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tandon A, Schiff D (2014) Therapeutic decision making in patients with newly diagnosed low grade glioma. Curr Treat Options Oncol 15:529–538. doi:10.1007/s11864-014-0304-6

    Article  PubMed  Google Scholar 

  12. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771

    CAS  PubMed  Google Scholar 

  13. Klein M (2009) Health-related quality of life aspects in patients with low-grade glioma. Adv Tech Stand Neurosurg 35:213–235

    Google Scholar 

  14. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström POO, Collette L, Piérart M, Mirimanoff R, Karim AB, Radiotherapy E, Brain Tumor G, The UKMRC (2004) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990. doi:10.1016/S0140-6736(05)67070-5

    Article  Google Scholar 

  15. Malmström A, Grønberg BHH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R, Nordic (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926. doi:10.1016/S1470-2045(12)70265-6

    Article  PubMed  Google Scholar 

  16. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. The Lancet Oncology 13:707–715. doi:10.1016/S1470-2045(12)70164-X

    Article  CAS  PubMed  Google Scholar 

  17. Hegi ME, Diserens A-CC, Gorlia T, Hamou M-FF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff ROO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331

    Article  CAS  PubMed  Google Scholar 

  18. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343. doi:10.1200/JCO.2012.43.2674

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre J-YY, Bernsen HJJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350. doi:10.1200/JCO.2012.43.2229

    Article  PubMed  Google Scholar 

  20. van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430. doi:10.1016/S1474-4422(07)70103-5

    Article  PubMed  Google Scholar 

  21. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978. doi:10.1093/emboj/20.24.6969

    Article  PubMed  PubMed Central  Google Scholar 

  22. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079–1086

    Article  CAS  PubMed  Google Scholar 

  23. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734–36741. doi:10.1074/jbc.M101287200

    Article  CAS  PubMed  Google Scholar 

  24. Acharya MR, Sparreboom A, Venitz J, Figg WD (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68:917–932. doi:10.1124/mol.105.014167

    Article  CAS  PubMed  Google Scholar 

  25. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206–222. doi:10.1016/j.ctrv.2007.11.003

    Article  CAS  PubMed  Google Scholar 

  26. Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86:504–509. doi:10.1016/j.ijrobp.2013.02.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB (2011) Potential role for valproate in the treatment of high–risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol 28:556–570. doi:10.3109/08880018.2011.563774

    Article  CAS  PubMed  Google Scholar 

  28. Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg 118:859–865. doi:10.3171/2012.10.JNS12169

    Article  CAS  PubMed  Google Scholar 

  29. Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15:961–967. doi:10.1093/neuonc/not057

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff ROO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164. doi:10.1212/WNL.0b013e31822f02e1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Bromberg JE, van den Bent MJ (2009) Oligodendrogliomas: molecular biology and treatment. Oncologist 14:155–163. doi:10.1634/theoncologist.2008-0248

    Article  CAS  PubMed  Google Scholar 

  32. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479

    Article  CAS  PubMed  Google Scholar 

  33. Hess-Stumpp H (2005) Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84:109–121. doi:10.1016/j.ejcb.2004.12.010

    Article  CAS  PubMed  Google Scholar 

  34. Walkinshaw DR, Yang XJ (2008) Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15:237–243

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, Witt O, Deubzer HE, Kulozik AE, Debus J, Weber K-JJ (2010) Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78:237–245. doi:10.1016/j.ijrobp.2010.03.010

    Article  CAS  PubMed  Google Scholar 

  36. Camphausen K, Scott T, Sproull M, Tofilon PJ (2004) Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10:6066–6071. doi:10.1158/1078-0432.CCR-04-0537

    Article  CAS  PubMed  Google Scholar 

  37. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang S-MM, Harari PM (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62:223–229. doi:10.1016/j.ijrobp.2004.12.088

    Article  CAS  PubMed  Google Scholar 

  38. Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA (2007) In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro Oncol 9:82–88. doi:10.1215/15228517-2006-032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380–386. doi:10.1002/ijc.20774

    Article  CAS  PubMed  Google Scholar 

  40. Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410–5415. doi:10.1158/1078-0432.CCR-08-0643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Detich N, Bovenzi V, Szyf M (2003) Valproate induces replication-independent active DNA demethylation. J Biol Chem 278:27586–27592. doi:10.1074/jbc.M303740200

    Article  CAS  PubMed  Google Scholar 

  42. Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ (2012) Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol 107:61–67. doi:10.1007/s11060-011-0725-z

    Article  CAS  PubMed  Google Scholar 

  43. Matheu A, Klatt P, Serrano M (2005) Regulation of the INK4a/ARF locus by histone deacetylase inhibitors. J Biol Chem 280:42433–42441

    Article  CAS  PubMed  Google Scholar 

  44. Idbaih A, Carvalho Silva R, Crinière E, Marie Y, Carpentier C, Boisselier B, Taillibert S, Rousseau A, Mokhtari K, Ducray F, Thillet J, Sanson M, Hoang-Xuan K, Delattre J-YY (2008) Genomic changes in progression of low-grade gliomas. J Neurooncol 90:133–140. doi:10.1007/s11060-008-9644-z

    Article  CAS  PubMed  Google Scholar 

  45. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T (2007) Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol 17:5–10

    Article  CAS  PubMed  Google Scholar 

  46. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, Gottlicher M (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22:3411–3420

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lucio-Eterovic AK, Cortez MAA, Valera ET, Motta FJ, Queiroz RG, Machado HR, Carlotti CG, Neder L, Scrideli CA, Tone LG (2007) Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 8:243. doi:10.1186/1471-2407-8-243

    Article  Google Scholar 

  48. Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, Pelicci PG, Chiocca S, Johnstone RW, Minucci S (2013) A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121:3459–3468. doi:10.1182/blood-2012-10-461988

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors confirm the originality of this work. The work was not submitted for publication to another journal.

Author information

Author notes

    Authors and Affiliations

    1. Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White Building Room, Gray 502, Boston, MA, 02114, USA

      Navid Redjal, Andrew Le, Brian P. Walcott & Brian V. Nahed

    2. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, 02114, Boston, MA, USA

      Clemens Reinshagen

    3. MGH Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, 50 Staniford Street, Boston, MA, 02114, USA

      Erin McDonnell

    4. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, 02114, MA, USA

      Jorg Dietrich

    Authors
    1. Navid Redjal
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Clemens Reinshagen
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Andrew Le
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Brian P. Walcott
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Erin McDonnell
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Jorg Dietrich
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Brian V. Nahed
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Navid Redjal.

    Ethics declarations

    Conflict of Interest

    The authors declare that they have no financial or other conflict of interest in relation to this research and its publication.

    Additional information

    Navid Redjal and Clemens Reinshagen have Contributed equally to this work.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (DOCX 21 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Redjal, N., Reinshagen, C., Le, A. et al. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. J Neurooncol 127, 505–514 (2016). https://doi.org/10.1007/s11060-016-2054-8

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s11060-016-2054-8

    Keywords

    Search

    Navigation